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Abstract
Background: Adipose tissue is a promising source of mesenchymal stromal cells (MSCs) for the treatment of tendon
disease. The goal of this study was to assess the effect of a single intralesional implantation of adipose tissue-derived
mesenchymal stromal cells (AT-MSCs) on artificial lesions in equine superficial digital flexor tendons (SDFTs).
Methods: During this randomized, controlled, blinded experimental study, either autologous cultured AT-MSCs
suspended in autologous inactivated serum (AT-MSC-serum) or autologous inactivated serum (serum) were injected
intralesionally 2 weeks after surgical creation of centrally located SDFT lesions in both forelimbs of nine horses. Healing
was assessed clinically and with ultrasound (standard B-mode and ultrasound tissue characterization) at regular
intervals over 24 weeks. After euthanasia of the horses the SDFTs were examined histologically, biochemically and by
means of biomechanical testing.
Results: AT-MSC implantation did not substantially influence clinical and ultrasonographic parameters. Histology,
biochemical and biomechanical characteristics of the repair tissue did not differ significantly between treatment
modalities after 24 weeks. Compared with macroscopically normal tendon tissue, the content of the mature collagen
crosslink hydroxylysylpyridinoline did not differ after AT-MSC-serum treatment (p = 0.074) while it was significantly
lower (p = 0.027) in lesions treated with serum alone. Stress at failure (p = 0.048) and the modulus of elasticity (p = 0.
001) were significantly lower after AT-MSC-serum treatment than in normal tendon tissue.
Conclusions: The effect of a single intralesional injection of cultured AT-MSCs suspended in autologous inactivated
serum was not superior to treatment of surgically created SDFT lesions with autologous inactivated serum alone in a
surgical model of tendinopathy over an observation period of 22 weeks. AT-MSC treatment might have a positive
influence on collagen crosslinking of remodelling scar tissue. Controlled long-term studies including naturally occurring
tendinopathies are necessary to verify the effects of AT-MSCs on tendon disease.
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Background
Tendon injuries are common in both human [1–3] and
equine [4–6] athletes. In horses, the superficial digital
flexor tendon (SDFT), which is located at the palmar
aspect of the limb, acts to store and release elastic en-
ergy and is subject to strains close to its functional limits
[7, 8]. Due to gradual accumulation of degenerative
damage during intensive training leading to partial
rupture, this tendon is prone to failure, especially in
racehorses [5]. Because of the high incidence, prolonged
recovery period and high re-injury rate, a plethora of
physical, medical and surgical interventions have been
applied over the years to improve quality of the repair
tissue; however, to date the ideal treatment concept has
not been found [9–11]. Potentially regenerative therap-
ies, in particular cell and blood-based substrates, have
gained interest over the last decade [12]. The adminis-
tration of multipotent cells, in particular autologous
mesenchymal stromal cells (MSCs) [13], or totipotent
embryonic stem cells (ESCs) [14, 15] into tendon defects
is suggested to have direct and indirect influences on
tendon healing. It is thus hypothesized that the injected
cells may either differentiate into cells capable of synthe-
sizing tendon matrix—that is, have a direct regenerative
effect [16–20]—or act by a paracrine effect through the
release of trophic mediators, growth factors and immu-
nomodulatory, angiogenic as well as anti-apoptotic
substances [21–26].
To date it is not clear which cell source is the ideal
choice to enhance tendon regeneration [27]. Comparing
different adipose tissue-based cell-rich substrates, adipose-
derived nucleated cells (ADNCs) are, by contrast with
adipose tissue-derived mesenchymal stromal cells (AT-
MSCs), a mixture of different cell types. The advantage is
that ADNCs are readily available within hours after tissue
harvest without the demand of cost and time for culture.
Multipotency has been proven for pericytes [28], which
form a subset of the ADNCs. However, AT-MSC culture
leads to a higher cell dose and theoretically to a greater
effect [29]. To the knowledge of the authors, however, it is
not clear which cell type contributes most to tendon heal-
ing [28, 30]. In an experimental equine collagenase model
study ADNCs had a limited effect on tendon healing but
led to histologically improved tendon organization and an
increase in cartilage oligomeric matrix protein (COMP)
expression [30].
The clinically most relevant sources of MSCs in equine
orthopaedics are bone marrow, adipose tissue and umbil-
ical cord blood [27, 31]. The advantages of adipose tissue
over bone marrow are that it is widely available and easily
accessible, and its MSC content is higher with a higher
proliferation capacity of AT-MSCs [32] and a slower sen-
escence than that of bone marrow mesenchymal stromal
cells (BM-MSCs) [27, 33, 34]. Despite the lack of a definite
set of surface markers to characterize equine tenocytes, a
recent study demonstrated that, compared with BM-
MSCs, umbilical cord blood MSCs and AT-MSCs express
collagen 1A2, collagen 3A1 and decorin at the highest
levels with the highest collagen type 1A2:3A1 ratio [32].
AT-MSCs show high expressions of the tendon markers
COMP and scleraxis [20, 32]. Furthermore, AT-MSCs
have already been used with promising results to treat
equine tendinopathies, as described in several uncon-
trolled case series [35–38]. In a controlled in-vivo ex-
perimental study, the implantation of AT-MSCs into
collagenase-induced SDFT core lesions resulted in
improved tendon fibre organization and decreased in-
flammatory infiltrate, as well as increased collagen type
I gene expression compared with the control limbs,
whereas no differences were seen in clinical parameters
and with B-mode ultrasonography [39]. In another
study from the same group using the collagenase-gel
model of tendinopathy, intralesional treatment with
AT-MSCs suspended in platelet concentrate prevented
progression of SDFT lesions and resulted in better
organization of collagen fibrils, less inflammation and
increased vascularity [40]. However, the relevance of
this model is questioned due to the strong acute
inflammatory response after collagenase injection,
which is unlike naturally occurring degenerative tendon
lesions, and due to difficulties in standardization of
lesions [41–44]. A recently introduced surgical model
of centrally located SDFT (core) lesions is thought to
mimic the characteristics of overuse tendinopathy more
realistically [43, 45–47].
Since the 1980s, B-mode ultrasonography has been
considered the gold standard for the diagnosis of tendi-
nopathy [48, 49]. Because of its limitations, such as the
lack of axial information, operator dependence, influence
of ultrasound beam angle and limited resolution,
however, the value of quantification of B-mode ultra-
sound images for the adequate assessment of repair is
questioned [50, 51]. Ultrasound tissue characterization
(UTC) is a new technique that was developed to analyse
echo pattern stability on a computerized basis [52, 53].
Transverse ultrasound (US) images are captured at regu-
lar distances over the long axis of the tendon, and are
reconstituted to a three-dimensional block of US infor-
mation with the help of custom-designed software.
Depending on the echo pattern stability over contiguous
images, four different echo types can be discriminated
with histo-morphology as a reference test [44, 52]. UTC
has been shown a viable diagnostic tool to monitor
experimental tendinopathies [44, 47, 54] and natural
tendon disease [55, 56] in horses and is increasingly used
for the assessment of (Achilles) tendon integrity in
humans [57–59]. Histologic examination is still the gold
standard to assess tendon healing [60] and commonly
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yields the most important results at the end of terminal
experimental studies when findings can be correlated to
those from other examination modalities (e.g. diagnostic
imaging) [30, 44, 45]. Another major component of
experimental tendon studies should be biomechanical
testing of tendon specimens to quantify functional
properties of the repair tissue which are potentially
representative for the resistance to strain in a clinical
setting [45, 61, 62].
To our knowledge, the effect of AT-MSCs has not
been tested experimentally in horses over a 6-month
period using a controlled blinded, randomized study
design with non-invasive monitoring and multimodal
end-stage evaluation of the repair tissue. Therefore, the
aim of this study was to assess whether a single intrale-
sional implantation of AT-MSCs suspended in autolo-
gous inactivated serum into surgically created lesions
leads to a reduction of inflammatory signs and improved
ultrasonographic, biochemical, biomechanical and histo-
logic characteristics compared with the application of
autologous inactivated serum alone.
Methods
Horses
Nine horses (eight warmbloods, one trotter) aged 3–6
years (mean 4 years) with a mean bodyweight of 545 kg
(range 498–607 kg) were included in this study. All
horses were housed in boxes and fed hay and cereals.
Prior to the study, none of the horses showed clinical
and/or ultrasonographic (B-mode, UTC) signs of fore-
limb SDFT disorders.
Surgical creation of lesions and adipose tissue harvest
Core lesions were surgically created in the SDFTs of
both forelimbs using the model introduced by Little and
Schramme [63] and modified by Bosch et al. [45] and
Schramme et al. [43]. All horses received meloxicam
(0.6 mg/kg bwt (IV)) preoperatively and 2 days postoper-
atively. No perioperative antimicrobials were adminis-
tered. A standard protocol for inhalation anaesthesia
was used and the horses were positioned in lateral
recumbency. After clipping and aseptic preparation, a
1.5-cm incision was made in the palmar midline, 2 cm
proximal to the proximal end of the common digital
flexor tendon sheath through the skin and the mesoten-
don into the tendon core. A 2.5-mm blunt conical ob-
turator (Karl Storz, Tuttlingen, Germany) was inserted
and guided proximally inside the tendon core under
ultrasonographic guidance over a distance of 7 cm.
Subsequently, a 3.5-mm burr (Abrador Burr 28200RN;
Karl Storz) was inserted in the tunnel that had been cre-
ated, activated and gradually pulled backwards over
20 seconds, while pressing the tendon against the tip of
the burr. Care was taken not to damage the dorsal
epitenon. Epitenon incisions were sutured in a simple
interrupted pattern with polyglactin 910 (Vicryl® 2-0
USP; Ethicon, Norderstedt, Germany), and skin incisions
were closed in a vertical mattress pattern with polyamide
(Dafilon® 2-0 USP; Braun Melsungen, Melsungen, Germany).
Double-layer bandages were applied and changed every 1–2
days until intralesional injection.
During the same general anaesthesia, the right paraxial
gluteal region was clipped and aseptically prepared. A 4-
cm skin incision was made in the cranio-caudal direction
and 20 g of adipose tissue was excised from the subcutis.
The skin was sutured with a vertical mattress pattern with
polyamide (Dafilon® 1 USP; Braun Melsungen).
Adipose tissue was stored in MSC medium containing
1 g/l Dulbecco’s Modified Eagle’s Medium (DMEM) with
25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) and 1% L-glutamine (DMEM with 25 mM
HEPES, with L-glutamine; PAA Laboratories, Pasching,
Austria), fetal bovine serum (PAA Laboratories) and 1%
penicillin/streptomycin (Penicillin-Streptomycin 100; PAA
Laboratories) at 5 °C and shipped to the laboratory
overnight.
AT-MSC isolation and culture
Adipose tissue was mechanically separated using a
scalpel blade and a tissue chopper. The tissue was
digested with 0.05% type IV collagenase (Sigma Aldrich,
Taufkirchen, Germany) and 0.025% protease (Dispase II;
Sigma-Aldrich) at 37 °C for 30 min until it was neutral-
ized by 10% fetal bovine serum (PAA Laboratories).
After centrifugation (200 × g, 10 min), the pellet was sus-
pended in 10 ml of Hanks’ buffer (HBSS 1× with Ca and
Mg; PAA Laboratories), centrifuged again with the same
settings, and the pellet containing the MSCs was sus-
pended in MSC medium in 75-ml polypropylene flasks
(T75 flask; BD Falcon, Franklin Lakes, NJ, USA) and
cultured at 37 °C and 5% CO2. The MSCs were selected
by plastic adhesion. MSCs were transfected with recom-
binant lentivirus particles expressing sequences of the pro-
moting region for transcription factor hUbiC (copGFP;
System Biosciences, Mountain View, CA, USA) to be able
to track the MSCs via autofluorescence, which was part of
another study presented elsewhere.
After 95–100% confluence of cells was reached, the
medium was removed and MSCs were washed once with
PBS (Dulbecco’s PBS without Ca and Mg; PAA Laborator-
ies). Adherent cells were separated with 3 ml of Trypsin/
EDTA solution (Trypsin/EDTA 1×; PAA Laboratories) for
5 min at 37 °C, which was checked by light microscopy.
After neutralization with 6 ml of MSC medium, the sus-
pension was transferred into a 15-ml polypropylene tube
(Conical tubes 15 ml; BD Falcon), centrifuged (200 × g,
5 min) and the pellet suspended in 10 ml MSC medium.
Cells were counted using a Neubauer counting chamber
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(Zählkammer Neubauer; LO Laboroptik, Friedrichsdorf,
Germany), and 10 × 106 MSCs were transferred into a
new 15-ml polypropylene tube and washed with 10 ml of
1 g/l DMEM with 25 mM HEPES and 1% L-glutamine.
After centrifugation, the pellet was suspended in 1 ml of
autologous serum. The serum had been inactivated previ-
ously at 56 °C for 30 min. The MSC-serum suspension
was transferred into a plastic tube (S-Monovette® 9 ml;
Sarstedt, Nümbrecht, Germany), stored on ice, shipped
overnight and kept at 4 °C until injection. AT-MSC
culture and processing was performed as described previ-
ously [46].
Immunophenotyping of AT-MSCs by flow cytometric
analysis
After isolation and expansion (passage 3) the AT-MSCs
were incubated with monoclonal and polyclonal antibodies
against CD14 (C2265-36; US Biological), CD29 (303015;
Biozol), CD34 (555820; BD Pharmingen), CD44 (103005;
Bio Legend), CD45 (555480; BD Pharmingen), CD90
(ab225; abcam) and CD117 (ab5616; Biozol) (Fig. 1). AT-
MSCs stained only with secondary antibodies (ab150105
(abcam), DAB087583 and DAB087693 (Dianova)) were
used as negative controls. Antibody binding was measured
using flow cytometric analysis (BD FACSCanto™ II with
BD FACSDiva™ 8.0.1 software).
Adipogenic, osteogenic and chondrogenic differentiation
of AT-MSCs
Differentiation of AT-MSCs was induced at passage 2 to
adipogenic, osteogenic and chondrogenic lineages. For
adipogenic differentiation, cells were seeded at a density
of 2 × 104 cells/cm2 in basal medium. After 24 hours,
medium was switched to Adipogenic Induction Medium,
consisting of DMEM High Glucose, supplemented with
10% FBS, 1% L-glutamine, 1% penicillin/streptomycin,
1 μM dexamethasone, 1 μM indomethacin, 500 μM 3-
isobutyl-1-methylxantine (IBMX) and 10 μg/ml human
recombinant insulin. Medium was changed twice a week
for 14 days. Lipid production being specific for adipo-
cytes was made visible by Oil Red staining (Fig. 2).
To induce osteogenic differentiation, AT-MSCs were
cultured in 24-well plates with DMEM Low Glucose with
10% FBS (MSC tested; Gibco), 1% L-glutamine (PAA La-
boratories), 0.1 μM dexamethasone (Sigma Aldrich) and
1 mM β-glycerophosphate (Sigma Aldrich) for 4 weeks.
Controls for osteogenic differentiation were treated under
the same conditions without dexamethasone and β-
glycerophosphate. The production of mineralized matrix
produced by osteoblasts was made evident by alkaline
phosphatase, Alizarin red and von Kossa staining (Fig. 3).
To demonstrate chondrogenic differentiation, the cells
were trypsinized and 5 × 105–1 × 106 cells/ml were resus-
pended in DMEMHigh Glucose, 1% penicillin/streptomycin,
1% L-glutamine, 10% FBS, with 1× Insulin–Transferrin–Sel-
enium (ITS) supplement, 1 mM sodium pyruvate, 100 nM
dexamethasone, 40 μg/ml proline, 50 μg/ml l-ascorbic acid-
2-phosphate and 10 ng/ml TGF-β1. Cells were centrifuged
for 10 min at 200 × g in 15-ml Falcon tubes. The tubes were
incubated with filter tops in a rack at 37 °C and 5% CO2.
After 2–4 days the pellets condensed. The cells were further
incubated in these tubes for 21 days. The medium was chan-
ged every 2–3 days. The production of proteoglycans being
specific for cartilage was visualized with Toluidine Blue and
Safranin-O staining (Fig. 4).
Intralesional treatment of tendons with AT-MSCs
Fourteen days after creation of the lesions, horses were
sedated with detomidine hydrochloride (0.015 mg/kg
bwt (IV)) and butorphanol (0.025 mg/kg bwt (IV)), the
hair over the palmar metacarpal region was clipped, the
skin was prepared aseptically and the Nn. palmares later-
alis and medialis were anaesthetized with 2.5 ml of 2%
mepivacaine solution.
The core lesion of one randomly assigned SDFT of
each horse was injected with 10 × 106 AT-MSCs sus-
pended in 1 ml of inactivated autologous serum, whereas
the lesion in the contralateral SDFT was injected with
1 ml of inactivated autologous serum to serve as an
intra-individual control. Randomization was carried out
by flipping a coin and the operator was not blinded to
the treatment modality.
Limbs were positioned manually to ensure equal
weight bearing. For the ultrasound-guided intralesional
injection, a 22-G needle was inserted from lateral at two
sites (3 and 5 cm proximal to the surgical scar in the
skin) and per site 0.5 ml of the inactivated serum con-
taining AT-MSCs (AT-MSC-serum group) or inactivated
serum alone (serum group) were injected intralesionally,
respectively. Care was taken that the injection proceeded
without resistance. A bandage was applied for 10 days
and changed every second day.
Exercise programme
All horses were subject to a standardized hand-walking
exercise programme as described previously by Bosch
et al. [45] (Additional file 1) on firm flat ground mainly
in straight lines. Horses were turned to the left and to the
right equally often. Trotting exercise was carried out on a
treadmill at 3.1 m/s.
Clinical and ultrasonographic examinations
A general clinical examination (body temperature, heart
rate, respiratory rate, appetite, limb function and com-
fort level) was performed daily.
Preoperatively, prior to intralesional injection at
2 weeks after surgery, and 3, 4, 5, 6, 8, 10, 12, 18, 21 and
24 weeks postoperatively, limbs were assessed clinically,
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Fig. 1 Flow cytometric analysis of cultured AT-MSCs from a representative study horse. Histograms indicate the immunophenotype of AT-MSCs
for CD14, CD29, CD34, CD44, CD45, CD90 and CD117. Results are displayed for the distribution of immunostained (green) and unstained (red) AT-
MSCs. All stained cells were positive for CD29, CD44 and CD90 while the signal for CD14 was weaker. No signal was detected for CD34, CD45
and CD117 (Colour figure online)
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via B-mode ultrasonography and with UTC. SDFT swell-
ing was determined by palpation as an increase in
diameter relative to normal tendon (0 = no increase, 1 =
increase by factor 1.5; 2 = increase by factor 1.5–2; 3 =
increase by more than factor 2) [56, 64, 65], skin
temperature over the SDFT was assessed manually (0 =
no abnormality; 1 =mild abnormality; 2 =moderate ab-
normality; 3 = severe abnormality) and surgical skin
wounds and injection sites were inspected. Lameness
was evaluated at walk during the first 18 weeks post sur-
gery, and additionally at trot from weeks 19 to 24 by an
experienced equine clinician being blinded to the treated
limb (five-grade score) [66].
Prior to ultrasonographic examinations, horses were
sedated with romifidine (0.04–0.08 mg/kg bwt (IV)) and
butorphanol (0.02 mg/kg bwt (IV)), and the hair on the
palmar aspect of the metacarpus was clipped and
shaved. The skin was washed with soap and degreased
with alcohol, and contact gel for ultrasound examination
was applied copiously. B-mode ultrasound examination
was carried out with a 6–15 MHz ultrasound probe (GE
ML 6-15; GE Healthcare, Wauwatosa, WI, USA) con-
nected to a Logiq E9 (GE Healthcare) using a standoff
pad and constant settings (frequency 13 MHz, gain 52,
depth 25 mm, single focal zone set at 15 mm depth).
The palmar metacarpus was divided into examination
zones from proximal to distal in the transverse (1A, 1B,
2A, 2B, 3A, 3B, 3C) and longitudinal plane (1, 2, 3) as de-
scribed earlier [67, 68]. Images were stored digitally and
analysed with a DICOM workstation programme (easy-
IMAGE®, easyVET®; IFS Informationssysteme, Hannover,
Germany). The cross-sectional area (CSA) of the SDFT
was determined on all transverse images. Values for each
examination zone were added to calculate the total cross-
sectional area (TCSA). Echogenicity and fibre alignment
were graded semi-quantitatively on longitudinal images of
each zone. Echogenicity was assigned a score of 0 (nor-
moechoic), 1 (hypoechoic), 2 (mixed echogenicity) or 3
(anechoic) and fibre alignment was graded according to
the estimated percentage of parallel fibre bundles in the
lesion: 0 (>75%), 1 (50–74%), 2 (25–49%) and 3 (<25%).
Scores for all levels were summarized to calculate the total
echo score (TES) and the total fibre alignment score
(TFAS), respectively [68]. All measurements were per-
formed by two experienced examiners blinded to treat-
ment modalities (FR, MH). Values for TCSA and scores
for TES and TFAS from both examiners were averaged.
For the UTC examination, a 10-MHz ultrasound probe
(10 L5 Smartprobe; Terason Ultrasound, Teratech
Corporation, Burlington, MA, USA) connected to a
laptop computer (MacBook Pro® 17 inch; Apple, Cuper-
tino, CA, USA) loaded with software for data acquisition
and analysis (UTC™ Software V.1.0.1 2010; UTC Imaging,
Stein, the Netherlands) was used. The probe was fixed in a
motorized tracking device with built-in standoff pad
(UTC-Tracker™; UTC Imaging). Settings (depth, gain,
focal zone) were standardized, and all examinations were
performed by the same operator (FG) with the horse bear-
ing weight equally on both forelimbs. With the help of the
tracking device, the probe moved automatically from
proximal to distal at constant speed over a distance of
12 cm. Sampling of transverse images was conducted
every 0.2 mm, including the surgical site as the reference
point for the analysis. The compiled 600 transverse US
images were reconstructed into a three-dimensional data
block of US information and stored digitally until the end
of the examination period. The stability of the echo pat-
tern of corresponding pixels in contiguous transverse
images was analysed (UTC2011® Analyser V1.0.1; UTC
Imaging). The following echo types were discriminated:
those generated by intact and fully aligned fascicles (echo
type I, green), those generated by discontinuous and less
aligned fascicles (echo type II, blue), those generated by a
mainly fibrillary matrix with accumulation of collagen fi-
brils not (yet) organized into fascicles (echo type III, red)
and those generated by an amorphous matrix and fluid
(echo type IV, black). A 4-cm-long tendon segment from
2 to 6 cm proximal to the scar in the epitenon was se-
lected for analysis by one examiner (FR), being blinded to
the treatment modality. Within this segment, every fifth
a b
Fig. 2 Adipogenic differentiation of equine AT-MSCs from a representative study horse. Photomicrographs of AT-MSCs (passage 2) taken 28 days
after induction of adipogenic differentiation (a). After Oil Red staining a high number of intracellular lipid-containing vesicles was detected
compared with the control without differentiation medium (b) (Colour figure online)
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colour-coded transverse image (distance between images
1 mm) was used to place a circular cursor (∅ 5 mm) in or
around the central core lesion, depending on its size.
These contours were interpolated and ratios of echo types
were analysed quantitatively as fractions of the determined
volume. Mean values for the proportion of each echo type
were calculated for all horses and for all time points. Ten
scans obtained at different time points and from different
horses were chosen randomly and analysed twice by the
same examiner to determine the intra-observer reliability
and by three examiners to determine the inter-observer
reliability.
Euthanasia and tissue harvest
Twenty-four weeks after creation of the lesion, all
horses were sedated and anaesthesia was induced
using a standard protocol. Thereafter, the horses were







Fig. 3 Osteogenic differentiation of equine AT-MSCs from a representative study horse. Photomicrographs of AT-MSCs (passage 2) taken on
day 28 after induction of osteogenic differentiation (A1–A3; C1–C3). By contrast to controls without differentiation medium (B1–B3; D1–D3),
deposition of extracellular calcium was detected by alkaline phosphatase (A1, C1), von Kossa staining (A2, C2) and Alizarin red staining (A3, C3)
(Colour figure online)
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Each SDFT was excised at the level of the carpus and
the fetlock and the scar of the former surgical en-
trance to the tendon was identified. A transverse seg-
ment of 1 cm was harvested from the lateral half of the
SDFT between 2 and 3 cm proximal to the entrance
portal. The half-core of the lesion could easily be iden-
tified in this segment and was excised with a micro-
tome blade and cut into three pieces that were snap
frozen and stored at –80 °C for biochemical analysis.
Macroscopically normal reference tissue was harvested
from an equivalent 1-cm-long segment taken between
12 and 13 cm proximal to the entrance portal; that is,
in the proximal metacarpal region at least 5 cm away
from the proximal end of the core lesion.
The medial halves of the SDFT segments 2–7 cm
proximal and 13–18 cm proximal to the epitenon scar
(macroscopically normal control tissue) were obtained
for biomechanical testing and stored in PBS-soaked
gauze at –20 °C until analysis. The lateral half of the
segment 4–6 cm proximal to the epitenon scar was
collected for histological analysis, fixed in 4% parafor-
maldehyde for 7 days and stored in PBS at 4 °C until
embedding in paraffin. Later, 5-μm longitudinal slices
of the core lesion including adjacent tissue were cut
starting from the centre of the tendon and stained
with haematoxylin and eosin (H&E).
Histologic examination
The centre of each tendon was independently judged
by two observers blinded to horse and treatment (FG,
FR). In total, five high-power fields (40× magnification)
per section were examined with a light microscope
(Leitz Laborlux 12; Leica, Wetzlar, Germany) using an
established score [45, 60] (Additional file 2). Score
values determined by each observer were calculated for
each parameter before score values of both examiners
were averaged.
Biochemical analysis
Glycosaminoglycans and DNA analysis
After lyophilization of tendon samples, the dry weight
was determined and they were digested overnight at
60 °C in 400 μl papain solution (2 mM cysteine, 1 U/ml
papain, 50 mM NaH2PO4 and 2 mM EDTA, pH 6.5). A
modified 1,9-dimethylmethylene blue (DMMB) dye bind-
ing assay was used to analyse the sulphated GAG concen-
tration [45].
To a 20 μl sample, 10 μl of 3% (w/v) bovine serum albu-
min and 250 μl of reagent (46 μM DMMB, 40 mmol/l gly-
cine and 42 mmol/l NaCl adjusted to pH 3.0 with HCl
(hydrochloric acid)) were added, and the absorbency at 525
and 570 nm was measured after 30 min. The assay was
standardized with shark chondroitin sulfate (1–100 μg/ml).
Quantification of total DNA was performed utilizing the
reaction of fluorescent dye [69]. Briefly, 2 ml Hoechst
33258 (Molecular Probes, Leiden, the Netherlands) fluor-
escent dye solution (0.1 pg/ml in 10 mM Tris, 1 mM
ethylenediaminetetraacetate (EDTA), 0.1 M NaCl pH 7.4)
was added to an 80 μl sample and, immediately after mix-
ing, fluorescence was measured using a LS-50B fluorim-
eter (Perkin Elmer, Norwalk, CT, USA), with excitation at
352 nm and emission at 455 nm. Salmon sperm (0–
20 μg/ml) was used as a standard. All results were
expressed as μg/mg dry weight tendon.
Collagen and crosslink analysis
Tendon samples were hydrolysed (110 °C, 18–20 h) in
600 μl of 6 M HCl for mass spectrometric determination
after lyophilizing for 24 hours. Hydroxyproline (Hyp) was
determined as a measure of total collagen content, and the
amino acid lysine (Lys), hydroxylysine (HLys, a measure
for the degree of lysine hydroxylation) and the pyridinoline
crosslinks hydroxylysylpyridinoline (HP) and lysylpyridino-
line (LP) as measures for the post-translational modifica-
tions of collagen. To the hydrolyzed tendon samples,
a b
Fig. 4 Chondrogenic differentiation of equine AT-MSCs from a representative study horse. Photomicrographs of AT-MSCs (passage 2) taken on
day 21 after induction of chondrogenic differentiation. The presence of glycosaminoglycans and collagen was detected by Toluidine Blue (a) and
Safranin O (b) (Colour figure online)
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200 μl of 2.4 mM homo-arginine was added after which
the samples were vacuum-dried and dissolved in 20%
acetonitrile containing 1.2 mM of tridecafluoroheptanoic
acid. Samples were centrifuged at 13,000 × g for 10 min.
Supernatants were subjected to high-performance liquid
chromatography (HPLC) and mass spectrometry (MS),
using a 4000 Q-TRAP mass spectrometer (MDS Sciex,
Foster City, CA, USA) at a source temperature of 300 °C
and a spray voltage of 4.5 kV. Amino acids were separated
on a Synergi MAX-RP 80A column (250 × 3 mm, 4 μm;
Phenomenex Inc., Torrance, CA, USA) at a flow rate of
400 μl/min, using a gradient from MilliQ® water to aceto-
nitrile, both containing 1.2 mM of tridecafluoroheptanoic
acid and 2.5 mM ammonium acetate. Amino acids were
identified by MS in multiple reaction mode using the mass
transitions 429.3/82.0 (HP), 413.3/84.0 (LP), 189.2/143.7
(homo-arginine), 147.2/130.2 (Lys), 163.2/128.1 (HLys)
and 131.8/67.8 (Hyp). Data were related to the recovery of
internal standard. Collagen content was calculated as
follows:
Collagen μgð Þ ¼ Hyp pmolð Þ = 300½   0:3
where 300 is the number of Hyp residues in one colla-
gen triple helix and 0.3 is deduced from the molecular
weight of collagen (30,000 Da).
Biomechanical testing
Tendon specimens were thawed at room temperature
for approximately 2 hours before trimming. Two strips
of 2 × 2 mm width and 50 mm length were cut from the
visible lesion and a single strip was harvested from a
tendon segment with macroscopically normal tissue
(further proximal to the lesion site) from each tendon
using a custom-designed cutting device [45, 70]. Speci-
mens were marked and stored in PBS-soaked gauze at
4 °C and tested within 2 hours. Before testing, the exact
CSA was measured at four locations along the length of
the specimen using a laser device (Laser Micro Diameter
LDM-110; Takikawa Engineering, Japan) and the average
CSA was calculated. Strips were fixed in the loading
device of a universal materials testing machine (Zwick
1445; Zwick, Germany) in a PBS bath and precondi-
tioned with 3% strain at 1 Hertz for seven cycles. After
that, specimens were loaded to failure with 0.5 mm/s. For
each specimen, force (F) and displacement were recorded.
The stress at failure (σmax) was calculated as follows:
σmax ¼ Fmax= CSA N=mm2 ¼ MPa
 
and the modulus of elasticity was derived from the
linear part of the stress–strain curve [45, 61]. Results of
the two specimens taken from macroscopically normal
tissue (left and right SDFTs) were pooled in one group.
Statistical analysis
Clinical, B-mode ultrasound, UTC, histology and biochem-
istry data were analysed using SAS® 9.3 (SAS Institute,
Cary, NC, USA). The assumption of a normal distribution
of quantitative parameters was examined using the Sha-
piro–Wilk test and visual assessment of distributions. In
normally distributed samples, parametric methods were
used: t test for paired observations and analysis of variance
for calculation of variance components (intra-class correl-
ation coefficient (ICC)). Otherwise, non-parametric tests
(Kruskal–Wallis test and Wilcoxon two-sample test) were
applied.
Data from biochemical testing, which were partly not
normally distributed, were tested using the Wilcoxon
signed-rank test (R version 3.0.2; The R Foundation for
Statistical Computing, Vienna, Austria). The Kruskal–
Wallis test was used to compare CSAs of specimens,
stress at failure and modulus of elasticity among all three
tested groups. Individual comparisons of the three
groups (AT-MSC-serum, serum, macroscopically normal
tissue) were performed using a Wilcoxon signed-rank
test with Bonferroni correction for multiple testing.
A significance level of α = 0.05 was applied. Intra-
observer and inter-observer repeatability of UTC mea-
surements and histology scores were calculated using
the ICC. A repeatability value > 0.75 was considered ex-
cellent, 0.75–0.4 as fair to good and <0.4 as poor [71].
Proc NESTED and Proc VARCOM were used for calcu-
lation of the coefficient of variance.
Results
Lesion creation, adipose tissue harvest and intralesional
treatment
Surgical creation of core lesions was successful in all
limbs; the epitenon was not damaged inadvertently in
any case. Harvest of adipose tissue, isolation and culture
of AT-MSCs was carried out without complications.
Immunophenotyping and trilineage differentiation of
cultured cells showed typical characteristics of MSCs
(Figs. 1, 2, 3 and 4) [72].
Intralesional injections were uneventful in all horses.
Clinical examination
No lameness was evident at walk until week 17 and at
walk and trot from week 18 to 24. All horses developed an
increase in skin temperature over the SDFT during the
course of the experiment, without differences between the
groups. Mild to moderate swelling of the palmar metacar-
pal region was palpable in both groups after induction of
lesions. This swelling decreased markedly until 3 weeks
and increased markedly again until week 8 after injection
in all limbs. Scores for palpable swelling remained consist-
ently high in the serum group, while they decreased con-
tinuously in the AT-MSC-serum group. This difference
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was weakly significant (p = 0.0497) at 21 weeks after sur-
gery. At the end of the observation period, palpable SDFT
swelling was mild in all horses. Two horses developed cel-
lulitis in the region of the surgical entrance, which healed
without pharmaceutical intervention.
B-mode ultrasonography
All horses developed bilateral tendon core lesions with
an ultrasonographic morphology similar to naturally
occurring tendon disease. There were no significant
differences in TCSA, TFAS (Fig. 5) and TES between
the groups at any point in time. Mean TCSA increased
markedly in both groups until 4 weeks and reached its
maximum at 8 weeks after lesion induction (AT-
MSC-serum, 803 mm2, serum, 793 mm2). TFAS in-
creased similarly and peaked at week 5 after lesion
induction (Fig. 5). TCSA and TFAS decreased again
until week 10.
Ultrasound tissue characterization
Intra-class correlation for UTC measurements was
excellent for intra-observer reliability (0.99) and
inter-observer reliability (0.80–0.97 depending on
echo type).
The development of echo type ratios within SDFT le-
sions over time is shown in Fig. 6. There was a strong
decrease of structure-related echo types I and II until
week 5 after lesion induction (Fig. 6a, b) and a concomi-
tant increase of non-structure-related echo types III and
IV in both groups (Fig. 6c, d), indicative for tissue dam-
age, loss of structural organization and inflammatory re-
sponse. Echo type III ratios indicating fibrillogenesis
peaked between weeks 6 and 8 postoperatively in both
groups. Echo type II ratios increased from weeks 6 to
18, which is indicative for a fibrillary matrix being orga-
nized into fascicles that are not yet aligned properly. The
significantly higher ratio of echo type II in the AT-MSC-
Fig. 5 B-mode ultrasonographic parameters. Development of ultrasonographic scores (mean ± SD) of SDFTs treated with AT-MSCs suspended in
autologous inactivated serum (solid lines) and autologous inactivated serum alone (dotted lines) over 24 weeks after surgical induction of tendon
injuries. a TCSA. b TFAS. AT-MSC adipose-derived mesenchymal stromal cell
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serum group in week 12 post surgery (p = 0.0326)
may be indicative for increased remodelling (Fig. 6b).
Simultaneously there was an increase in echo type I
ratios without any differences between the groups.
From week 12 post surgery onwards, all echo type
ratios did not change markedly until the end of the
study.
Gross pathologic examination
At post-mortem gross examination, injection sites were
still visible as two unilateral swellings of the lateral as-
pect of the tendon. Scar tissue was visible within the
centre of the tendons as the core lesion (Fig. 7). Macro-
scopically, there were no differences visible between the
groups.
Fig. 6 Ultrasound tissue characterization. Development of echo type ratios for SDFTs treated with AT-MSCs suspended in autologous inactivated
serum (solid lines) and autologous inactivated serum alone (dotted lines) over 24 weeks after surgical induction of tendon injuries. a Echo type I.
b Echo type II. c Echo type III. d Echo type IV. *Significant difference between groups. AT-MSC adipose-derived mesenchymal stromal cell
ba
Fig. 7 Gross pathologic examination of SDFTs. a Transverse and b longitudinal section of a serum-treated tendon segment 24 weeks after surgical
induction of tendinopathy, 2 and 2–5 cm proximal to the surgical entrance into the tendon, respectively. The centrally located scar tissue is pale
to intensively pink, partly reddish and well demarcated from surrounding ivory-coloured tendon tissue. The scar is nearly circular in shape on the
transverse and appears as an oblong area on the longitudinal section (Colour figure online)
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DNA, GAG, collagen and crosslink content
The dry weight of samples from AT-MSC-serum-treated
and from serum-treated tendon lesions as well as sam-
ples from macroscopically normal tissue from the same
tendons did not differ significantly (p > 0.05). The con-
tents of GAG, DNA, Hyp, total collagen, HP, LP and
HLys did not differ between lesions from the AT-MSC-
serum group and the serum group. Tendon lesions
treated with AT-MSC-serum and those treated with
serum alone contained both more GAG (AT-MSC-serum,
p = 0.0078; serum, p = 0.0039) and DNA (AT-MSC-serum,
p = 0.0039; serum, p = 0.0039) and less Hyp (AT-MSC-
serum, p = 0.0195; serum, p = 0.0078) and total collagen
(AT-MSC-serum, p = 0.0195; serum, p = 0.0078) than
macroscopically normal tissue from the same tendons
(Table 1). LP and HLys content was the same in tendon
lesions treated with AT-MSC-serum and serum alone and
in macroscopically normal tissue (p > 0.05). Tendons
treated with AT-MSC-serum had the same HP content as
tendons treated with serum alone (p = 0.25) and macro-
scopically normal tendon tissue (p = 0.0742). By con-
trast, normal tendon tissue contained more HP than
tendon treated with autologous inactivated serum alone
(p = 0.0273).
Histology
Intra-class correlation for histology scores was excellent
for inter-observer reliability (0.77–0.97 depending on
score/sub-score). The lesions could be identified clearly
on all H&E-stained slices. Histology was indicative for
an incomplete restoration of structural integrity and a
high metabolic activity (Fig. 8). There were no significant
(p < 0.05) differences between the AT-MSC-serum and
serum groups alone with respect to total scores, scores
for fibre arrangement, scores for metabolic activity and
sub-scores for fibre structure, fibre alignment, morphology
of tenocyte nuclei, variations in cell density or vas-
cularization. Scores for structural integrity and metabolic
activity remained high after the 24-week observation
period (Fig. 9).
Biomechanical testing
Cross-sectional areas of tendon strips were not signifi-
cantly different between AT-MSC-serum-treated lesion
tissue, serum-treated lesion tissue and macroscopically
normal tendon tissue (p = 0.11). Stress at failure and modu-
lus of elasticity did not differ between AT-MSC-serum-
treated tendons and those treated with serum (p = 1)
(Fig. 10). Compared with macroscopically normal tendon
tissue, stress at failure and modulus of elasticity were
significantly lower in AT-MSC-serum-treated lesion tissue
(p = 0.048 and p = 0.001, respectively) as well as in serum-
treated lesion tissue (p = 0.004 and p = 0.002, respectively).
Discussion
Standardized central lesions were successfully induced in
the SDFT of horses and longitudinally followed using
standard and more sophisticated monitoring techniques
for 24 weeks before in-depth histological, biochemical
and biomechanical tissue analysis.
The current study shows that a single treatment with
10 × 106 AT-MSCs suspended in inactivated autologous
serum does not have a lasting effect on signs of inflamma-
tion and does not substantially improve ultrasonographic
histologic, biochemical or biomechanical characteristics
of surgically created SDFT core lesions over a 24-week
period compared with inactivated autologous serum alone.
However, the fact that the hydroxylysylpyridinoline (HP)
content in the AT-MSC-serum treatment group is closer
to the normal situation may potentially indicate improved
collagen crosslinking.
Table 1 Biochemical parameters of SDFTs treated with AT-MSCs suspended in autologous inactivated serum (AT-MSC-serum) and
autologous inactivated serum alone (serum) and macroscopically normal tendon tissue (normal) from the same tendons 22 weeks
after treatment
Group
Parameter AT-MSC-serum (n = 9) Serum (n = 9) Normal (n = 18)
DNA (μg/mg dwt) 3.91 ± 0.96a 4.24 ± 1.31a 1.99 ± 0.30b
GAG (μg/mg dwt) 21.38 ± 11.44a 26.80 ± 10.26a 6.47 ± 1.16b
Hyp (mg/mg dwt) 0.067 ± 0.001a 0.062 ± 0.012a 0.083 ± 0.009b
Total collagen (mg/mg dwt) 0.510 ± 0.076a 0.469 ± 0.093a 0.635 ± 0.071b
HP (mol/mol col) 0.196 ± 0.025ab 0.184 ± 0.026b 0.238 ± 0.040a
LP (mol/mol col) 0.016 ± 0.005a 0.017 ± 0.007a 0.013 ± 0.005a
HLys (mol/mol col) 6.90 ± 1.76a 7.39 ± 2.37a 7.38 ± 1.96a
Values presented as mean ± standard deviation
col collagen, dwt dry weight, GAG glycosaminoglycans, HLys Hydroxylysine, HP hydroxylysylpyridinoline, Hyp Hydroxyproline, LP lysylpyridinoline, AT-MSC adipose-
derived mesenchymal stromal cell, SDFT superficial digital flexor tendon
a,bDifferent superscript letters indicate significant differences (p < 0.05) between treatment groups
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Hydroxylysine (HLys) is produced during a post-
translational enzymatic modification process in tendon
and is needed for the formation of the mature crosslinks
HP and LP [73, 74]. Newly formed collagen within a
lesion is less crosslinked than in mature tissue, which
was most likely caused by enzymatic cleavage after the
surgical trauma and the subsequent formation of
more stable crosslinks during the remodelling phase
resulting in repair tissue with higher tensile strength
and stiffness [75].
The HP crosslink concentration per molecule of colla-
gen in our study was the same in normal tissue as in
AT-MSC-treated lesion tissue while lesion tissue treated
with inactivated serum alone contained significantly less
HP than macroscopically normal tissue. Despite the lack
of significance between the AT-MSC-serum and serum
groups this might be interpreted as a sign of superior
crosslinking; that is, a better or more advanced repair
after AT-MSC treatment.
The contents of lesion tissue in HLys and in LP as
expressed per molecule of collagen were the same in
tendon lesions treated with AT-MSC-serum and serum
alone and in macroscopically normal tissue, showing
that these post-translational modifications were by
contrast not affected by creation of the lesions and the
treatment modalities.
An increased GAG content of healing tendon lesions
reflects a high tenocyte metabolism and an increased
production of extracellular matrix. There is controversy
about increased GAG content in tendon repair: on the
one hand, degenerated tendon regions including fibrous
scar tissue have been shown to contain higher concen-
trations of sulphated GAGs than normal tendons in
humans and horses [76–78]. On the other hand, an in-
creased GAG content as expressed per DNA has been
interpreted as a sign of improved tendon healing in a re-
cent equine study after intralesional platelet-rich plasma




Fig. 8 Histology of surgically induced SDFT lesions 22 weeks after treatment. a–f Longitudinal specimens of tendon lesions treated with AT-MSCs
suspended in autologous inactivated serum (a, c, e) and autologous inactivated serum alone (control; b, d, f) stained with H&E (a, b, scale bar =
200 μm; c, d, e, f, scale bar = 100 μm). Fibril arrangement was mostly unidirectional (a–d), with some cases showing large regions without any
regular fibre arrangement (e, f; yellow asterisk) in both groups. Specimens showed variations in cell density (a–d) and regions with high cellularity
and vascularization after both treatment modalities (e, f; black asterisks) (Colour figure online)
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saline-treated control tendons in the latter study and in
another study testing a plasma product [79] were similar
to the GAG content in both groups of the current study
using the same surgical model of tendinopathy, respect-
ively. This also corresponds well to findings in naturally
injured SDFTs that were saline treated and contained
significantly more GAG than corresponding BM-MSC-
treated as well as untreated control tendons, which were
relatively uninjured [13]. In the current study, GAG con-
tents in tendon lesions were higher than in normal
SDFT tissue from more proximal regions of the injured
tendons. These GAG contents in turn were very similar
to those from mid-metacarpal SDFT tissue from mature
horses in another study [80], suggesting that the prox-
imal metacarpal region is suitable as a control to com-
pare biochemical parameters of mid-metacarpal SDFTs
Fig. 9 Histomorphological scores (Aström and Rausing [60], modified by Bosch et al. [45]). Mean histomorphological scores (± SD) for surgically
induced SDFT lesions treated with AT-MSCs suspended in autologous inactivated serum (AT-MSC) and with autologous inactivated serum alone
(control) 22 weeks after treatment. Total scores (green) include values from sub-scores for fibre structure (struct.), fibre alignment (align.), morphology
(morph.) of tenocyte nuclei, variations (variat.) in cell density in cell density and vascularization (vascul.). Scores for structural (struct.) integrity and
metabolic (metab.) activity summarize values from sub-scores displayed in blue and red, respectively. Scores and sub-scores did not differ between
treatment modalities (p < 0.05). AT-MSC adipose-derived mesenchymal stromal cell (Colour figure online)
Fig. 10 Biomechanical parameters. Stress at failure and modulus of elasticity (measure of tensile stiffness of materials) of surgically induced SDFT
lesion tissue treated with AT-MSCs suspended in autologous inactivated serum (AT-MSC + serum) and autologous inactivated serum alone (serum)
24 weeks after creation of lesions and 22 weeks after treatment. Macroscopically normal tendon tissue (normal) was harvested from a proximal
segment of the same tendons. AT-MSC adipose-derived mesenchymal stromal cell
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and that SDFTs did not reach normal GAG content after
treatment at the end of the observation period in the
current study [80, 81], which implies that the end stage
of healing had not been reached.
In the current study, lesions treated with AT-MSCs had
the same content in total collagen and Hyp as tendons
treated with autologous inactivated serum alone. Although
replacement of tenocytes with new ones resulting from
tenogenic differentiation after engraftment of MSCs with
consecutive production of extracellular matrix (e.g. colla-
gen, GAG) is a potential mechanism of the therapy used
[28], the findings do not support that this mechanism of
action played a major role in the current study.
Collagen and Hyp contents, however, were significantly
lower than in macroscopically normal tendon tissue which
contained as much collagen as unaltered tissue in a previ-
ous study [82]. The finding that lesion tissue contains less
collagen than normal tendon is in accordance with a pre-
vious study using the same model [47].
Collagen types could have been differentiated between
the more elastic type I and type III in the current study.
However, MSCs as well as autologous serum have the
potential to influence the expression of these collagen
types during tendon repair [32, 62, 65]. The time frame
in which expression of the collagen type I to III ratio
reaches its optimum during the remodelling phase has
not been clearly defined [41], so it remains unclear
whether differentiation of collagen types would have
helped to show which treatment modality was more
beneficial in the current study.
Collagen content correlates positively with the modu-
lus of elasticity representing stiffness and with the stress
at failure of the tendon strips in the current study, be-
cause both parameters were significantly lower in lesion
tissue than in macroscopically normal tendon tissue.
This is a typical characteristic of scar tissue with low
maturity [61] and also proves that tendon healing was
still ongoing at the terminal stage of the current experi-
ment. It has to be concluded that AT-MSCs did not
significantly influence the biomechanical properties in
surgically created SDFT lesions 22 weeks after treat-
ment, as did PRP in a similar model [45]. Stress at fail-
ure, one of the most important indicators for tensile
strength of tendons [61], was significantly lower after
AT-MSC-serum treatment and after treatment with
serum alone than in macroscopically normal tendon tis-
sue harvested from a proximal segment from the same
tendons. Based on the knowledge that intact tendon
tissue from the proximal metacarpal region normally has
similar biomechanical properties as tissue from the mid-
metacarpal region [83], this finding suggests that scar
tissue has not regained its original strength 22 weeks
after AT-MSC treatment. Findings from the present
study show that it is beneficial to include macroscopically
normal tissue as a second control group during biomech-
anical testing as an intra-individual reference for normal
tendon tissue which was not reported in similar studies
previously [45, 79].
Biomechanical properties of the repair tissue are closely
related to functionality [45, 61, 84], which becomes clinic-
ally manifest by the recurrence rate of natural tendon
disease in horses and to a lesser extent by persisting lame-
ness [41]. Horses in the present study did not show signs
of lameness until the end of the study period, which is in
accordance with the observation that, in contrast to hu-
man patients with Achilles tendinopathy, chronic tendon
pain does not play a major role in horses [23]. However,
the sensitivity of clinical examination alone is limited to
monitoring lameness, especially in cases of bilateral ten-
don injury [3]. This could have been improved by using
computerized gait analysis, but this was not available
during the experiment. The study period and the exercise
regimen could have been extended to determine the
recurrence rate of tendinopathy, one of the most reli-
able parameters of long-term functionality. However,
this was considered ethically unacceptable in an ex-
perimental study.
Swelling of SDFTs, another clinical parameter of
inflammation, was less (weak significance) in AT-MSC-
treated tendons than in control tendons only at a single
time point (i.e. at 21 weeks after lesion induction).
Because the ultrasonographically determined tendon
cross-sectional area (TCSA) did not differ between
groups at any time, the findings during palpation might
be attributed to a decrease in subcutaneous swelling ra-
ther than in tendon diameter. Swelling was determined
by palpation, a diagnostic modality which is subject to
some inaccuracy, so it remains questionable whether
AT-MSCs really influenced subcutaneous swelling dur-
ing the remodelling phase (e.g. by reflux of the cell
suspension during treatment).
In the current study, no significant reduction of
clinical signs of inflammation and no reduction of fluid
and/or cell accumulation during ultrasonography were
recorded after injection of AT-MSC-serum during the
acute inflammatory phase when compared with the ef-
fect of serum alone, which corroborates earlier in-vivo
findings [39] - although an increased echogenicity of
collagenase-induced SDFT lesions was seen after AT-
MSC application in a later study from the same group
[40]. Another experimental in-vivo study using the same
surgical model as in the current study showed a signifi-
cant reduction of fluid and cell accumulation by means
of UTC early after intralesional treatment with PRP,
which was interpreted as a reduction of inflammation
[45]. The authors of the current study would have ex-
pected similar effects after AT-MSC injection, because
these cells are known to exert anti-inflammatory effects
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[85–87]: human AT-MSCs led to a reduced inflamma-
tory response in synovial cells from patients with osteo-
arthritis by inhibition of pro-inflammatory cytokines
such as IL-1β and IL-6 [85]. Recently it has been shown in
a canine model of tendon transection that collagen sheets
seeded with AT-MSCs promote an anti-inflammatory
M2-type macrophage phenotype [87]. Immunomodula-
tory actions of MSCs are thought to be dose and time
dependent [29], so that a higher MSC dose, implantation
at an earlier or later time point after lesion creation or
repeated injections might have led to different results. To
the authors’ knowledge, no experimental data exist con-
cerning the ideal dose and timing of MSC implantation
[28, 88]. On the one hand, it is hypothesized that there is
a direct positive dose–effect relation [89]; on the other, ex-
perimental data show cytotoxic effects of high MSC doses
[90]. In a rabbit experimental study, BM-MSC–collagen
composites were used to repair patellar tendon defects
and MSC concentrations of 4 × 106 and 8 × 106 cells/ml
did not lead to additional biomechanical and histological
improvement compared with 1 × 106 cells/ml [91]. In the
current study, the cell dose of 10 × 106 AT-MSCs was
based on recommendations from previous clinical and ex-
perimental trials [23, 39, 92]. The time of injection might
have been too late to induce early anti-inflammatory ef-
fects, which were achieved with PRP injections as early as
7 days after lesion creation in the same model of tendino-
pathy [45]. Although the ideal point of time for MSC
treatment is not known [28], it is hypothesized that ten-
dons should be treated after the initial inflammatory phase
and before fibrous tissue has formed [88]. Advised times
range from 7 to 30 days between lesion creation and treat-
ment with adipose tissue-derived cells has been described
in experimental studies [30, 39, 40]. Using high numbers
of pure MSCs for treatment, cell culture per se implies a
delay of cell injection. In a large clinical study, horses
treated <5 weeks after injury had a lower re-injury rate
than horses treated later, but this difference was not
significant [93].
In the current study the authors decided to postpone
the MSC injection for another week, because lesions
seemed to be less developed at ultrasonography 7 days
after induction than in previous studies using the same
model [43, 45, 47], which might be attributed to the use
of a different burr during creation of the lesions, to con-
finement of the horses to box rest instead of exercising
them after lesion induction, or to the model itself. The
surgical model ideally creates a compartment similar to
that typically seen in degenerative strain-induced tendon
disease [43, 47]. Creating these lesions requires general
anaesthesia, which is a disadvantage, but this model is
better standardized and considered less painful for
horses than induction of core lesions with collagenase, a
model which rather reflects the inflammatory component
of tendinopathy. The response to these interventions in
terms of the expansion of the lesion seems to be less pro-
nounced in the surgical model [42, 43]. The inflammatory
response in the current study was most prominent rela-
tively late - that is, at 5 weeks after surgery and 3 weeks
after cell injection, as shown by UTC (peak in echo type
IV) - so that at this time potential anti-inflammatory ef-
fects ascribed to AT-MSCs [85–87] might already have
been weaker than the endogenous inflammatory response.
In other words, the AT-MSCs could possibly not exert
their effect adequately in an environment of only mild
to moderate inflammation at the time of injection.
Interestingly, in another in-vivo study using a collage-
nase model, AT-MSCs which were implanted 30 days
after lesion creation (i.e. approximately 2 weeks later
than in the current study) led to decreased inflamma-
tory cell infiltration as determined by histology of biop-
sies at 30 and 120 days after treatment [39]. This
finding suggests that later AT-MSC implantation at the
end of a pronounced inflammatory phase might be
more efficient, but the significant differences between
both experimental models of tendinopathy may also
play a role here.
Depending on the mode of action of MSCs implanted
into tendon lesions (i.e. paracrine effects versus de-novo
synthesis of tendon tissue), a decline of MSC population
over time during the inflammatory and proliferative
phase may be an explanation for the lack of substantial
differences between the AT-MSC and control groups.
Death of the MSCs is a potential reason: in an equine
surgical model of tendinopathy, less than 5% of BM-
MSCs survived more than 10 days and only 0.02% sur-
vived over 90 days after implantation [14]. Allogeneic
embryonic stem like cells (ESCs), by contrast, were de-
tectable at a constant level over 90 days in the same
study, which shows that development of stem cells from
different sources may vary after implantation. High
numbers of AT-MSCs could be detected with different
modalities as long as 9 weeks after implantation into
surgically created SDFT lesions [94]. Labelled AT-MSCs
injected into experimentally induced equine tendon le-
sions were partly found to remain viable and integrated
in the lesion tissue after 24 weeks, although numbers of
cells decreased over time, and MSCs could even be de-
tected in SDFT lesions of the contralateral limb [95].
Together with the observation that labelled cells were
retrieved in the peritendinous tissue near the injection
site [94, 95], this implies a potential effect of the MSC
treatment on the contralateral defect and a loss of MSCs
effectively available in the treated lesion. Both effects
may have limited the effect of the treatment.
It would have been valuable to test in the current trial
whether the therapy exerted an anti-apoptotic effect on
tenocytes, an effect which has been attributed to AT-
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MSCs [87]. However, to address this it would have been
necessary to take tendon biopsies to perform immuno-
staining with markers for apoptotic cells during the in-
flammatory phase, given the duration of the study. This
was discarded because of the potential impact of the
procedure on tendon healing. Further, the attraction of
precursor cells as another potential mechanism of AT-
MSC therapy is more relevant during early phases of
tendon healing. Even after harvesting of tendon biopsies,
it would have been a challenge to estimate this effect
merely via determination of the cellularity, because there
is no precursor cell-specific marker.
For injection, cells must be suspended in a medium,
which may consist of phosphate-buffered saline (PBS)
[30] or autologous blood serum, the latter being consid-
ered a more adequate suspension medium by some
authors [14, 96]. However, it was shown that autologous
serum, cultivated in glass tubes at 37 °C for 24 hours,
contains significant amounts of IL-1ra and IL-10 [97],
which implies that serum alone might influence tendon
healing [65]. Instead of fresh serum [39], thermally inac-
tivated autologous serum was used in the present study
and also injected into control group lesions. Alterna-
tively, control lesions could have been left without punc-
ture and treatment, but puncture alone has been shown
to support drainage of early fluid accumulation and could
theoretically guide peritendineal precursor cells into the
lesion and thereby have a therapeutic effect [98, 99]. For
the same reason, repeat biopsies were not used in the
current study compared with previous studies [40]. Only
two more control groups—one without any puncture, and
one with puncture alone but without injection—could
have ruled out these effects. However, a much larger study
population would have been needed.
Twelve weeks after surgery, the ratio of type II echoes
representing discontinuous fascicles not yet aligned into
lines of stress was significantly higher in AT-MSC-
treated lesions than in control lesions, which might be
indicative for a pro-aligning influence of implanted AT-
MSCs on the early organization of tendon matrix into
tendon bundles [44, 54], potentially mediated by direct
or paracrine coordinating effects of AT-MSCs on fibro-
blasts. However, differences did not last until the end of
the observation period, and no effects on the percentage
of type I echoes (i.e. intact tendon tissue) were evident
in the AT-MSC group, so it remains unclear whether the
finding is biological reality or due to chance. Clinical
relevance seems limited.
Ratios for type I echoes, representative for fully
aligned tendon bundles, did not reach those for intact
tendon tissue inside the core lesion in terminal UTC
scans. This indicates that there was still no complete
restoration of perfectly aligned tendon bundles after
24 weeks, as expected after this timeframe [82]. The
finding that ratios of all echo types only changed mildly
in the current study after week 12 is different from that
of Bosch et al. [45], who used a similar model of tendi-
nopathy and found further improvement; that is, a
more pronounced decrease of the echo type IV ratio
and an increase of the echo type I ratio between weeks
12 and 24 after PRP treatment of surgically induced
tendon lesions.
Results of histology, biochemical analyses and bio-
mechanical testing, which were only performed post
mortem 22 weeks after treatment, correlate well with
the UTC findings observed previously [44, 45]. None of
these diagnostic modalities showed differences between
AT-MSC-serum-treated tendons and serum-treated con-
trols. Compared with macroscopically normal SDFT tis-
sue from the same horses there were significantly higher
DNA and GAG contents, and lower Hyp and total colla-
gen and HP contents. At the same time tenocyte nuclei
were rounded, showing the more tenoblastic cell type,
and cell density showed high local variations. Also,
histologic scores for fibre structure and fibre alignment
were increased in both groups. All of these findings are
indicative for relatively high metabolic activity and
ongoing tissue repair and remodelling at the end of the
observation period (i.e. in the remodelling or maturation
phase) [41]. It can be argued that to evaluate the end
stage of tendon repair an observation period of 1 year
would have been even more appropriate [82]. However,
it had been shown previously that the phases of early re-
modelling or maturation when newly formed collagen
type I fibres are organized into bundles and orientate
themselves into lines of stress take place between ap-
proximately days 45 and 120 after lesion induction
[100], and it is hardly conceivable that differences would
have been noted at 1 year but not after 24 weeks.
In AT-MSC-treated lesions, no difference in vascularization
was found histologically using a subjective five-point
scale in this study. However, in a more detailed analysis
reported elsewhere [46] in which all clearly identifiable
vessels on the entire tissue section were counted in the
same specimen, there was a significantly higher number of
vessels in AT-MSC-treated versus control tendons. This
finding, together with the increase in Doppler signal de-
tected at 2 weeks post treatment [46], shows that the
methodology used in the current study was obviously not
sensitive enough to detect these relatively minor differ-
ences. In other equine experimental studies, an increase in
Doppler signal could be detected at 6 weeks after implant-
ation of AT-MSCs suspended in platelet concentrate into
artificial SDFT lesions [40], whereas intralesional PRP in-
jection led to an almost continuous increase in Doppler
signal in another investigation [101]. Stimulation of angio-
genesis by AT-MSCs was also postulated by several
authors [22, 86] while others [90] showed endothelial cell
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apoptosis and capillary degeneration after application of
rat BM-MSCs in vitro. Neovascularization is of utmost
importance to assure transportation of cells and growth
factors towards and away from the lesion site during the
inflammatory and proliferative phases of extrinsic tendon
healing [41]. However, there is controversy about the
effects of a prolonged increase in vascularity, which is
discussed elsewhere [46, 60, 102, 103].
Conclusions
The effect of a single intralesional injection of cultured
AT-MSCs suspended in autologous inactivated serum
was not superior to the treatment of surgically created
SDFT lesions with autologous inactivated serum alone
in a surgical model of tendinopathy over an observation
period of 22 weeks. AT-MSC treatment might have a
positive influence on collagen crosslinking and therefore
possibly on tensile stress resistance of remodelling scar
tissue. Ultrasound tissue characterization (UTC) was a
viable tool to monitor tendon healing non-invasively and
the findings correlated well with results from end-stage
histology, biochemistry and biomechanical testing, which
proved that despite the onset of the remodelling phase,
tendon healing was not completed after a period of
24 weeks. Randomized controlled long-term studies in-
cluding naturally occurring tendinopathies are necessary
to put the results of the current study into perspective
before intralesional AT-MSC injection can be recom-
mended (or rejected) as a viable option for the treatment
of tendon disease.
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